Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lilly sifting its biotech portfolio; Lilly's project portfolio

Revision of the agreement between Eli Lilly and Co. and Cor Therapeutics Inc. (CORR), announced last week, is the fifth research collaboration Lilly has amended in the past six months as the pharma company streamlines its research programs.

A Lilly spokesperson said its research now is focused on cardiovascular disease, bacterial and viral infections, cancer, central nervous

Read the full 563 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers